Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: A randomised controlled trial

Diabetologia

Volumn 54, Issue 8, 2011, Pages 2103-2112

  Van Raalte, D H ^a   Brands, M ^b   Van Der Zijl, N J ^a   Muskiet, M H ^a   Pouwels, P J W ^a   Ackermans, M T ^b   Sauerwein, H P ^b   Serlie, M J ^b   Diamant, M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Glucocorticoids; Glucose intolerance; Insulin resistance; Intermediary metabolism

Indexed keywords

GLUCOCORTICOID; PLACEBO; PREDNISOLONE;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ENERGY EXPENDITURE; FATTY ACID OXIDATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HUMAN; HUMAN EXPERIMENT; HYPERINSULINEMIA; INSULIN RELEASE; LIPID METABOLISM; LIPOLYSIS; LOW DRUG DOSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL;

ADULT; BIOLOGICAL TRANSPORT; BLOOD GLUCOSE; DOUBLE-BLIND METHOD; GLUCOCORTICOIDS; HUMANS; INSULIN; LIPOLYSIS; MALE; PREDNISOLONE; YOUNG ADULT;

EID: 79960921598     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2174-9     Document Type: Article

References (46)

1. Bijlsma JW, van der Goes MC, Hoes JN, Jacobs JW, Buttgereit F, Kirwan J (2010) Low-dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy. Ann NY Acad Sci 1193:123-126
2. Hernandez-Rodriguez J, Cid MC, Lopez-Soto A, Espigol-Frigole G, Bosch X (2009) Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med 169:1839-1850
3. Salvarani C, Cantini F, Hunder GG (2008) Polymyalgia rheumatica and giant-cell arteritis. Lancet 372:234-245 (Pubitemid 351997438)
4. Parker BJ, Bruce IN (2007) High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus 16:387-393 (Pubitemid 47122211)
5. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W (2006) American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130:935-939 (Pubitemid 43374542)
6. van Raalte DH, Ouwens DM, Diamant M (2009) Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur. J Clin Invest 39:81-93
7. Buttgereit F, Da Silva JA, Boers M et al (2002) Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 61:718-722 (Pubitemid 34787710)
8. Wajngot A, Giacca A, Grill V, Vranic M, Efendic S (1992) The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders. Proc Natl Acad Sci USA 89:6035-6039
9. Larsson H, Ahren B (1999) Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity. Diabetologia 42:936-943 (Pubitemid 29369601)
10. Gravholt CH, Dall R, Christiansen JS, Moller N, Schmitz O (2002) Preferential stimulation of abdominal subcutaneous lipolysis after prednisolone exposure in humans. Obes Res 10:774-781 (Pubitemid 135687518)
11. Taskinen MR, Kuusi T, Yki-Jarvinen H, Nikkila EA (1988) Short-term effects of prednisone on serum lipids and high density lipoprotein subfractions in normolipidemic healthy men. J Clin Endocrinol Metab 67:291-299
12. Short KR, Bigelow ML, Nair KS (2009) Short-term prednisone use antagonizes insulin's anabolic effect on muscle protein and glucose metabolism in young healthy people. Am J Physiol Endocrinol Metab 297:E1260-E1268
13. Fernandez-Rodriguez E, Stewart PM, Cooper MS (2009) The pituitary-adrenal axis and body composition. Pituitary 12:105-115
14. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J (1994) Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 154:97-101 (Pubitemid 24018107)
15. Gulliford MC, Charlton J, Latinovic R (2006) Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 29:2728-2729 (Pubitemid 44912208)
16. Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, van der Heijden GJ (2009) Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 68:1833-1838
17. Tushuizen ME, Bunck MC, Pouwels PJ et al (2007) Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. Diabetes Care 30:2916-2921 (Pubitemid 350083144)
18. Tushuizen ME, Pouwels PJ, Bontemps S et al (2010) Postprandial lipid and apolipoprotein responses following three consecutive meals associate with liver fat content in type 2 diabetes and the metabolic syndrome. Atherosclerosis 211:308-314
19. van Raalte DH, Nofrate V, Bunck MC et al (2010) Acute and 2-week exposure to prednisolone impair different aspects of betacell function in healthy men. Eur J Endocrinol 162:729-735
20. Ackermans MT, Ruiter AF, Endert E (1998) Determination of glycerol concentrations and glycerol isotopic enrichments in human plasma by gas chromatography/mass spectrometry. Anal Biochem 258:80-86 (Pubitemid 28163147)
21. 2O are higher than those measured with [2-13C]glycerol. J Clin Endocrinol Metab 86:2220-2226
22. Geukers VG, Oudshoorn JH, Taminiau JA et al (2005) Short-term protein intake and stimulation of protein synthesis in stunted children with cystic fibrosis. Am J Clin Nutr 81:605-610
23. Finegood DT, Bergman RN, Vranic M (1987) Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes 36:914-924 (Pubitemid 17136807)
24. Steele R (1959) Influences of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 82:420-430
25. Frayn KN (1983) Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 55:628-634 (Pubitemid 13044099)
26. Clore JN, Thurby-Hay L (2009) Glucocorticoid-induced hyperglycemia. Endocr Pract 15:469-474
27. Corpeleijn E, Saris WH, Blaak EE (2009) Metabolic flexibility in the development of insulin resistance and type 2 diabetes: effects of lifestyle. Obes Rev 10:178-193
28. Henriksen JE, Alford F, Vaag A, Handberg A, Beck-Nielsen H (1999) Intracellular skeletal muscle glucose metabolism is differentially altered by dexamethasone treatment of normoglycemic relatives of type 2 diabetic patients. Metabolism 48:1128-1135 (Pubitemid 29418282)
29. Ruzzin J, Wagman AS, Jensen J (2005) Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia 48:2119-2130 (Pubitemid 41416925)
30. Djurhuus CB, Gravholt CH, Nielsen S et al (2002) Effects of cortisol on lipolysis and regional interstitial glycerol levels in humans. Am J Physiol Endocrinol Metab 283:E172-E177 (Pubitemid 34686683)
31. Djurhuus CB, Gravholt CH, Nielsen S, Pedersen SB, Moller N, Schmitz O (2004) Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans. Am J Physiol Endocrinol Metab 286:E488-E494 (Pubitemid 38292701)
32. Macfarlane DP, Forbes S, Walker BR (2008) Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol 197:189-204 (Pubitemid 351696232)
33. Birkenhager JC, Timmermans HA, Lamberts SW (1976) Depressed plasma FFA turnover rate in Cushing's syndrome. J Clin Endocrinol Metab 42:28-32
34. Miyoshi H, Shulman GI, Peters EJ, Wolfe MH, Elahi D, Wolfe RR (1988) Hormonal control of substrate cycling in humans. J Clin Invest 81:1545-1555
35. Bonadonna RC, Groop LC, Zych K, Shank M, DeFronzo RA (1990) Dose-dependent effect of insulin on plasma free fatty acid turnover and oxidation in humans. Am J Physiol 259: E736-E750 (Pubitemid 20385723)
36. Gelding SV, Coldham N, Anyaoku V, Heslop K, Halliday D, Johnston DG (1993) Differential metabolic actions of biosynthetic insulin analogues in normal man assessed by stable isotopic tracers. Diabet Med 10:470-476 (Pubitemid 23163767)
37. Nakada MT, Stadel JM, Poksay KS, Crooke ST (1987) Glucocorticoid regulation of beta-adrenergic receptors in 3T3-L1 preadipocytes. Mol Pharmacol 31:377-384 (Pubitemid 17069805)
38. Rojas FA, Hirata AE, Saad MJ (2003) Regulation of insulin receptor substrate-2 tyrosine phosphorylation in animal models of insulin resistance. Endocrinology 21:115-122 (Pubitemid 36936350)
39. Lundgren M, Buren J, Ruge T, Myrnas T, Eriksson JW (2004) Glucocorticoids down-regulate glucose uptake capacity and insulin-signaling proteins in omental but not subcutaneous human adipocytes. J Clin Endocrinol Metab 89:2989-2997 (Pubitemid 38766398)
40. Saad MJ, Folli F, Kahn JA, Kahn CR (1993) Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J Clin Invest 92:2065-2072 (Pubitemid 23304579)
41. Vegiopoulos A, Herzig S (2007) Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol 275:43-61 (Pubitemid 47259280)
42. Slavin BG, Ong JM, Kern PA (1994) Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes. J Lipid Res 35:1535-1541 (Pubitemid 24291214)
43. Schakman O, Gilson H, Thissen JP (2008) Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 197:1-10 (Pubitemid 351566920)
44. Dessein PH, Joffe BI (2006) Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 54:2765-2775 (Pubitemid 44497755)
45. Willi SM, Kennedy A, Wallace P, Ganaway E, Rogers NL, Garvey WT (2002) Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin. Diabetes 51:2895-2902
46. Rosen J, Miner JN (2005) The search for safer glucocorticoid receptor ligands. Endocr Rev 26:452-464 (Pubitemid 40691300)